Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1995-06-07
1997-04-29
Weddington, Kevin E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
514538, 514567, 514724, 5147722, A61K 31195, A61K 31045, A61K 3124
Patent
active
056249608
ABSTRACT:
An orally administrable drug formulation containing levodopa and carbidopa, and having a short release time, is disclosed. The formulation is useful in the treatment of Parkinson's disease.
REFERENCES:
patent: 3584113 (1971-06-01), Takebe et al.
patent: 3769424 (1973-10-01), Bayne
patent: 4424235 (1984-01-01), Sheth et al.
patent: 4832957 (1989-05-01), Dempski et al.
patent: 4900755 (1990-02-01), Dempski et al.
patent: 4983400 (1991-01-01), Dempski et al.
Noboru et al., "Increasing solubility of tyrosin or 3,4-dihydroxypehnylalanine," Chemical Abstracts, 882:10, Abs. No. 64498u Mar. 10, 1975, Columbus, Ohio.
Albert Frank-Michael
D arr Alfred
Fl other Frank-Ulrich
Freitag Sabine
Haase Margit
ISIS Pharma GmbH
Weddington Kevin E.
LandOfFree
Orally administrable drugs for the treatment of central dopamine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Orally administrable drugs for the treatment of central dopamine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Orally administrable drugs for the treatment of central dopamine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-706190